Manufacturers: Theralase Technologies Inc.
Light-activated drug: Ruvidar (TLD-1433) is administered by intravesical instillation (1 hour of drug instillation, 1 hour of light activation), then activated by the TLC-3200 Medical Laser System; upon light activation it targets bladder cancer cells directly.
BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS) with or without papillary disease (±Ta/T1); investigational agent in Phase II clinical development (Study II), not yet approved.
1 associated conditions
